drugset / Trial / NCT07661095
A Study of CRD3874-SI in People With Leukemia
RandomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to find out whether CRD3874-SI is a safe treatment for participants with acute myeloid leukemia (AML).
Timeline
- Start
- 2026-06-15
- Primary completion
- 2028-06-15
- Completion
- 2028-06-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CRD3874-SI | Unknown | 0.6 mg/kg | — |
| Subject | CRD3874-SI | Unknown | 0.9 mg/kg | — |
| Subject | CRD3874-SI | Unknown | 1.4 mg/kg | — |